Stifel Reiterates Hold Rating on DENTSPLY SIRONA (XRAY)

Stifel analyst Jonathan D. Block reiterated a Hold rating and $28.00 price target on DENTSPLY SIRONA (NASDAQ: XRAY).

The analyst commented: "Encouragingly, DENTSPLY SIRONA continues to streamline operations in an effort to drive EPS. Specifically, SKU rationalization and plant optimization opportunities should allow EPS to move higher despite 2025/2026 revenue growth that we expect will fall below the company’s LRP goal (+4-6%). While cost saving opportunities exist, we continue to have a more modest view of top-line growth. The biggest headwind may come from the CTS division as equipment remains under pressure and CTS’ decremental margin has been notable. The PS2 launch should help, and we look for the impact that falling interest rates may have on E&I, but we still forecast modest revenue growth in 2025E (CTS -1.1%). For other divisions, we believe reinvigorating implants has proved challenging, we have previously touched on Byte’s challenges (regulatory) and we question SureSmile’s inroads into Ortho. For Consumables, patient volumes remain tepid, and pricing power appears limited due to increasing private label uptake."

For an analyst ratings summary and ratings history on DENTSPLY SIRONA click here. For more ratings news on DENTSPLY SIRONA click here.

Shares of DENTSPLY SIRONA closed at $27.05 yesterday.

You May Also Be Interested In

• Qatar In Talks With US, Iran To Deescalate - NYT
• United Parks & Resorts (PRKS) PT Raised to $55 at Mizuho
• Applied Materials (AMAT) PT Raised to $650 at Stifel on 'Improved Financial Performance'